The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience
Abstract
Background Type 2 diabetes mellitus, obesity, and the metabolic syndrome (MS) have been growing in prevalence in the USA and are independent risk factors for the development of hepatocellular carcinoma (HCC). Nonalcoholic fatty liver disease (NAFLD), the hepatic manifestation of the MS, with or without nonalcoholic steatohepatitis (NASH) can predispose to HCC in the absence of cirrhosis or advanced fibrosis. Nevertheless, the US literature investigating non-cirrhotic HCC in the setting of NAFLD/NASH and MS is lacking.Aim To describe a retrospective case series of patients who developed HCC without cirrhosis in the setting of NAFLD/NASH or features of the MS.Methods We identified NAFLD/NASH-associated HCC cases arising in the absence of cirrhosis between January 2010 and September 2012 from a tumor board database at Brooke Army Medical Center (BAMC).Results Of 44 cases of HCC reviewed, six cases of non-cirrhotic HCC associated with NAFLD/NASH and/or MS were identified. Only one patient underwent partial hepatectomy with curative intent. The other five might have been candidates for potential curative partial hepatectomy or liver transplantation had they been diagnosed earlier.Conclusion Our case series highlights the development of NAFLD/NASH and MS-associated HCC in the absence of cirrhosis in the US population and raises the important question of HCC screening for this at-risk group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“in another case series of 44 individuals who developed MASLD-related HCC between 2010 and 2012, only one individual without cirrhosis (out of six) underwent liver resection, while the late diagnosis impeded curative treatments in the others. 236”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [236]
Citations
Cites
Jemal, A., Bray, F., Ferlay, J., Ward, E., & Forman, D. (2011) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 55,044
Erdogan, D., Heijnen, B. H. M., Bennink, R. J., Kok, M., Dinant, S., Straatsburg, I. H., Gouma, D. J., & van Gulik, T. M. (2004) · Liver International · doi:10.1111/j.1478-3231.2004.00901.x · Cited by 11,656
The metabolic syndrome—a new worldwide definition
Alberti, K. G. M., Zimmet, P., & Shaw, J. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67402-8 · Cited by 9,352
Management of Hepatocellular Carcinoma: An Update Δσ
Bruix, J., & Sherman, M. (2011) · Hepatology · doi:10.1002/hep.24199 · Cited by 8,135
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. Adults
Calle, E. E., Rodriguez, C., Walker-Thurmond, K., & Thun, M. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021423 · Cited by 7,696
Prevalence and Trends in Obesity Among US Adults, 1999-2008
Flegal, K. M. (2010) · JAMA · doi:10.1001/jama.2009.2014 · Cited by 7,580
Alberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2006.01858.x · Cited by 6,597
Management of Hepatocellular Carcinoma *
Bruix, J., & Sherman, M. (2005) · Hepatology · doi:10.1002/hep.20933 · Cited by 5,913
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El‐Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,479
Inflammation and insulin resistance
Shoelson, S. E. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29069 · Cited by 4,769
Cited by
Sorted by citations
Items 101–111 of 111
Development of a Pediatric Model of Nafld in Neonatal Iberian Pigs
Hernandez, G. V. (2019) · DigitalCommons - CalPoly (California State Polytechnic University) · doi:10.15368/theses.2019.107
NAFLD, Hepatocellular Carcinoma, and Extrahepatic Cancers
Younes, R., & Bugianesi, E. (2020) · Springer eBooks · doi:10.1007/978-3-319-95828-6_10
Pellicano, A. J., Mullan, S., Goldberg, I. D., & Prakash Narayan, A. (2021) · Processes · doi:10.3390/pr9091516
(2022) · American Registry of PathologyArlington, Virginia eBooks · doi:10.55418/9781933477183-9
Die nichtalkoholische Steatohepatitis (NASH) als Ursache erhöhter Leberwerte
Puengel, T., & Tacke, F. (2023) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1994-1722 · Cited by 1
Lysosomal Disturbances in Metabolic Disorders
Li, M. (2024) · Research Publications (Maastricht University) · doi:10.26481/dis.20241213ml
Hernáez, R., & Kanwal, F. (2025) · Springer eBooks · doi:10.1007/978-3-031-90225-3_3
Malignant Hepatocellular Tumors and Precursor Lesions
Vyas, M., & Zhang, X. (2025) · Pracatical anatomic pathology · doi:10.1007/978-3-031-97506-6_18
Murtha-Lemekhova, A., Fuchs, J., Feiler, S., Schulz, E., Teroerde, M., Kalkum, E., Klotz, R., Billeter, A., Probst, P., & Hoffmann, K. (2022) · Figshare · doi:10.6084/m9.figshare.19101828
Lin, Y.-C., Wang, J.-R., Su, T., Chen, Y.-J., Lien, H., George, E. S., Yang, L.-Y., Hsiao, T.-H., Lin, H.-Y., Wang, Y.-C., et al. (2026) · Trials · doi:10.1186/s13063-026-09819-9
Metadata
- Authors
- Perumpail, R. B., Wong, R. J., Ahmed, A., & Harrison, S. A.
- Affiliations
- Stanford Medicine (US)
- Alameda Health System (US)
- Brooke Army Medical Center (US)
- Corresponding author
- Perumpail, Ryan B.
- Venue
- Digestive Diseases and Sciences
- Published
- 2015-08-07
- Volume
- 60
- Issue
- 10
- Pages
- 3142-3148
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W1901124675
- Cited by
- 111
- References
- 45
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 9 · 2023: 2 · 2022: 9 · 2021: 16 · 2020: 19 · 2019: 13 · 2018: 16 · 2017: 14 · 2016: 6 · 2015: 2
- FWCI
- 7.49
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Hepatology › Liver physiology and pathology
- Keywords
- hepatocellular carcinoma, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, metabolic syndrome, non-cirrhotic liver cancer, type 2 diabetes, obesity, liver cirrhosis, partial hepatectomy, liver transplantation, HCC screening
- MeSH terms
- Aged, Female, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Male, Middle Aged, Prognosis, Retrospective Studies, United States, Cohort Studies, Comorbidity, Incidence, Survival Rate, Databases, Factual, Age Distribution, Sex Distribution, Risk Assessment, Metabolic Syndrome, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
